"instanceType","uuid:ID","versionIdentifier","rationale","id"
"StudyVersion","781c9ff6-2dda-4f17-b407-68b37a36b942","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
